From Lesion-Level Risk to Patient-Level Impact.

Elucid is driving the evolution from population health-based treatment decisions to truly personalized, lesion-level cardiovascular care.

FFR‑CT and Stenosis Under FDA Review

Plaque-IQ^TM

The only FDA-cleared plaque assessment tool powered by non-invasive CT Virtual Histology™

Elucid’s Plaque-IQ was trained and validated on ground-truth histology, the gold standard for plaque characterization, to deliver comprehensive patient, vessel, and lesion-level plaque composition and quantification data beyond Hounsfield Unit Thresholds. It is the only non-invasive plaque analysis indicated for use in the coronary and carotid arteries.

FFR‑CT¹

Remove the blindfold: Integrating plaque biology and plaque-based physiology for smart clinical decisions

Elucid’s FFR‑CT¹ goes beyond the physical properties of the vessel and the lesion to include biological and morphological properties as well. The performance of the vessel during maximum hyperemia is dependent upon plaque composition, making highly accurate plaque and FFR‑CT both necessary for patient treatment decisions. Elucid’s is the first non-invasive FFR‑CT analysis solution to take this into consideration, offering concordance between plaque data and FFR‑CT data.

The first and only CT-based plaque analysis indicated for the carotid anatomy

Plaque-IQ is the first and only CT-based plaque analysis software indicated for both the coronary and carotid anatomies.

Carotid Plaque-IQ can help physicians identify carotid plaques at risk for rupture and develop patient-specific treatment pathways to prevent and monitor against ischemic stroke. When used for both the coronary and carotid arteries, Plaque-IQ non-invasively delivers a quantitative and qualitative assessment of systemic atherosclerotic risk and enables the ability to perform both coronary and carotid plaque analysis in a single scan.

Non-invasive CT Virtual Histology^™

Plaque insights based on ground truth histology, the gold standard for characterization of plaque

Elucid’s foundation is uniquely focused on histology-validated plaque and biointegrated FFR‑CT¹ – what we call CT Virtual Histology – including the only CT-derived plaque analysis to also be validated for use in the carotid.

LRNC

The Only Non-Invasive Assessment Tool Capable of Identifying LRNC

For both its coronary and carotid applications, Elucid’s Plaque-IQ is capable of identifying highly-vulnerable lipid-rich necrotic core (LRNC), a plaque type strongly linked with cardiovascular risk.²^‚³ This offers direct insights into high-risk plaque features associated with heart attack and stroke, measuring true disease rather than directional proxies. By focusing on true disease biology rather than population-based risk estimates, this approach is designed to help physicians prioritize and personalize treatment for each individual patient.

Complete Transparency through Accurate, Condordant Plaque and FFR‑CT¹

Two Data Outputs From One Source Make Concordance Possible

Elucid strives to offer complete transparency to physicians with an approach grounded in the notion that concordance between plaque and FFR‑CT can only occur when the two outputs originate from the same source data. Both plaque and FFR‑CT are needed to make informed patient treatment decisions – and both must be highly accurate. Elucid and only Elucid delivers concondance between plaque data and FFR‑CT data. Since our FFR‑CT data is plaque-derived, the output is interpretable and actionable – helping physicians make better patient treatment decisions.

Results Delivered in Two Ways

Plaque-IQ delivers plaque quantification, luminal stenosis¹ and CAD-RADS™ scoring¹ to meet clinical workflow needs with a lesion-level view of coronary and carotid plaque, including LRNC. This detail helps inform patient-specific care decisions, including medical and cath lab decisions. Our transparent, segment-by-segment breakdown is automatically summarized in a clinical dashboard as well as a physician-validated PDF report.

Straightened Multi-Planar Reconstruction (MPR) – Visual confirmation of the entire vessel path for intuitive review of plaque distribution and stenosis severity

Transparent Segmentation – Automated metrics for every branch, from the Left Main to the distal segments, with color-coded plaque morphology mapping. Physicians can layer Plaque-IQ images over the raw CT to show vessel and wall segmentation, and the ability to view plaque by type. A fully-interpretable model allows physicians to see how investigational FFR analysis is derived from plaque

CAD-RADS™ Classifications at a Glance – Instant summary cards for plaque burden, highest stenosis, and standardized scoring to help physicians make personalized clinical decisions.

CAD-RADS is a trademark of Society of Cardiovascular Computed Tomography (SCCT). Elucid Bioimaging is not affiliated with, endorsed by, or sponsored by SCCT.

For complete CAD-RADS consensus documents, please refer to the following: https://www.journalofcardiovascularct.com/article/S1934-5925(22)00240-4/fulltext

Reimbursement

Medicare and commercial coverage for Elucid’s Plaque-IQ provides broader access, enabling clinicians to get ahead of heart attack and stroke for a large, diverse patient population across the U.S. The following resources are intended to help providers navigate billing and reimbursement for Elucid’s products.

CPT Codes

Coronary CT Angiography (CCTA): CPT 75574
Plaque-IQ: CPT 0623T-0626T- Jan 1-75577

U.S. Insurer Coverage Map

Click on your state to find coverage policies for CCTA, Plaque-IQ and FFR‑CT¹

Clinical Evidence

Recent Abstracts

Histology Validation

Elucid’s Plaque-IQ algorithms were validated on histopathologic specimens, including calculations of anatomic structure and calculations of tissue characteristics. The histopathologic validation demonstrated the following performance:

Plaque Type	Elucid's Plaque-IQ^TM FDA Validation to Histology (r =)
Total Plaque	0.99
Calcified	0.95
Non-Calcified	0.86
Lipid Rich Necrotic Core (LRNC)	0.88

*LRNC Area includes areas of LRNC and Intra-Plaque Hemorrhage as identified by pathologists
**Data on file from K241524

Partner with Us

Elucid values and encourages a collaborative approach to improve today’s clinical and economic outcomes and the future of personalized management for CAD. If you are interested in submitting a proposal for a research study, please contact us.

References

¹FFR‑CT and Stenosis pending FDA review

²Ozkaya, Ibis A.N., Ahmadi, A, Ramasamy, A, et al. Presented at SCCT 2026; Abstract 461.

³Bagherzadeh, S, Aldana-Bitar, J, Char, T, et al. Presented at SCCT 2026; Abstract 492.

⁴Bagherzadeh, S, Aldana-Bitar, J, Char, T, et al. Presented at SCCT 2026; Abstract 492.

⁵Aldana-Bitar, J, et al. Manuscript in press.

⁶Kolossvary et al, JCCT 2026.